Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > FY2019 H1 Earnings
FY2019 H1 Earnings
-
8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
-
Bullish New Drugs Mitigated Vesicare/Tarceva Patent Cliff: Astellas CEO
November 1, 2019
-
Daiichi Sankyo Ramps Up R&D Investment for ADC, 16 Studies Added to DS-8201
November 1, 2019
-
Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
-
Despite a Hold by Key Panel, Ono Sees Cachexia Drug Launch in April-September 2020
November 1, 2019
-
Xtandi Helps Astellas Counter Vesicare/Tarceva LOEs in April-September
November 1, 2019
-
Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
-
Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
-
Shionogi’s Half-Year Sales Slip 4.4% after Xofluza Milestone Gain
October 31, 2019
-
Mitsubishi Tanabe to Give Another Try for Radicava’s EU OK, but in Oral Form: Chief
October 31, 2019
-
Mitsubishi Tanabe Suffers 10% Sales Slide in 1st Half on Gilenya Royalty Row
October 31, 2019
-
Eisai Sees Brisk Sales of Global Brands, but Earnings Slump on One-Off Factors
October 31, 2019
-
Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings
October 31, 2019
-
Taisho’s Prescription Drug Sales Suffer Double-Digit Decline in H1, due to Capital Tie-Up Dissolution with Toyama Chemical
October 31, 2019
-
To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…